CRP and inflammatory bowel disease: In the total IBD cohort, and for CD separately, serum levels of C-reactive protein (CRP) were significantly lower at baseline in patients who eventually responded to vedolizumab induction therapy, as compared to primary non-responders (IBD: 3.4 [1.3;9.5] vs. 7.0 [3.2;16.8] mg/L, respectively, p < 0.05, Table 1).